实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (5): 507-510.doi: 10.3969/j.issn.1672-5069.2014.05.015

• 病毒性肝炎 • 上一篇    下一篇

聚乙二醇干扰素联合利巴韦林治疗获极快速病毒学应答的初治基因1型慢性丙型肝炎患者疗效观察*

丁岗强, 康谊, 尚佳, 刘俊平, 魏群锋, 肖二辉, 曾艳丽   

  1. 450003 郑州市 河南省人民医院感染病科
  • 收稿日期:2014-02-19 出版日期:2014-10-31 发布日期:2016-04-11
  • 通讯作者: 尚佳,E-mail: shangjia666@126.com
  • 作者简介:丁岗强,男,37岁,医学博士,主治医师
  • 基金资助:
    河南省医学科技攻关计划项目(201203090)

Extremely rapid virologic response in naive patient with chronic hepatitis C with genotype 1 virus infection receiving pegylated interferon and ribavirin treatment

Ding Gangqiang, Kang Yi, Shang Jia   

  1. Department of Infectious Diseases,Provincial People’s Hospital,Zhengzhou 450003,Henan Province,China
  • Received:2014-02-19 Online:2014-10-31 Published:2016-04-11

摘要: 目的观察获得极快速病毒学应答的初治基因1型慢性丙型肝炎患者,在继续接受36 w聚乙二醇干扰素α-2a联合利巴韦林治疗后的疗效。方法将基线HCV RNA水平>400000 IU/ml、接受聚乙二醇干扰素α-2a(180 μg/w)联合利巴韦林(1000~1200 mg/d)治疗2 w后HCV RNA阴转的基因1型慢性丙型肝炎初治患者,随机分为两组,分别接受36 w和48 w治疗,在停药后随访24 w,观察疗效。结果本研究共纳入40例患者,两组各20例。治疗36 w患者在治疗结束时病毒学应答(ETVR)、持续病毒学应答(SVR)和复发率分别为100% (20例)、90% (18例)和10% (2例),治疗48 w患者ETVR、SVR和复发分别为95% (19例)、90% (18例)和5.3% (1例),两组比较无统计学差异(P>0.05);在40例患者,基线HCV RNA水平与SVR呈负相关(OR=0.422,95%CI 为0.05~0.29,P=0.007);在治疗36 w患者,基线HCV RNA<6×107IU/ml患者SVR显著高于HCV RNA≥6×107IU/ml患者(P=0.005),但在治疗48 w患者,未发现这种差异(P=0.063)。结论对于基线HCV RNA水平>400000 IU/ml的基因1型慢性丙型肝炎初治患者,接受聚乙二醇干扰素α-2a联合利巴韦林治疗,如在2 w时获得病毒学应答,治疗36 w疗程与48 w疗程的SVR相当。

关键词: 慢性丙型肝炎, 干扰素α, -2a, 极快速病毒学应答, 疗效

Abstract: Objective To observe the extremely rapid virologic response(ERVR) in naive patient with chronic hepatitis C with genotype 1 virus infection receiving pegylated interferon and ribavirin treatment. Methods Forty naive hepatitis C patients with genotype 1 infection had baseline serum HCV RNA≥400000 IU/ml and they were treated with peginterferon-alpha-2a at dose of 180 μg per week and ribavirin at dose of 1000-1200 mg/d. After 2 week treatment,they all got so-called extremely rapid virologic response and then,they were randomly divided into two groups,e.g. 20 patients continued the regimen for 36 weeks(group 1) and another 20 patients received the therapy for 48 weeks(group 2). All patients were followed-up for 24 weeks after discontinuation. Results The end-of-treatment virologic response (ETVR),sustained virologic response(SVR) and recurrence rate of patients in group one were 100%,90% and 10%,respectively,while they were 95%,90% and 5.3% in group 2. There was no statistical differences between the two groups;There was a negative correlation between baseline serum HCV RNA levels and SVR (OR=0.422,95%CI 0.05-0.29,P=0.007) in the 40 patients;The SVR in patients with baseline serum HCV RNA<6×107IU/ml was higher than that in patients with baseline serum HCV RNA≥6×107IU/ml in group 1(P=0.005),but not in group 2(P=0.063). Conclusions The ERVR in naive patients with chronic hepatitis C receiving peginterferon-alpha-2a plus ribavirin treatment suggests relatively less anti-viral regimen and the same efficacy.

Key words: Hepatitis C, Interferon- alpha-2a, Extremely rapid virologic response, Efficacy